EP11.03-38 Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy

Soo Mee Lim(Asan Medical Center), D. Kim(Yonsei University), Hyun Ae Jung(Samsung Medical Center), K.C. Toh(IQVIA (United Kingdom)), Sung Hee Lim(Samsung Medical Center), K H Kim(Chonnam National University Hospital), Jae Hyun Kim(Seoul National University), Mi Jung Lee(Yonsei University Health System), Xi Zhao(IQVIA (United Kingdom)), Sung‐Soo Yoon(Seoul National University Hospital), Daniel Lee(Ulsan College), Hyun Sik Jeong(Ulsan College), Helena A. Yu(Memorial Sloan Kettering Cancer Center)
Journal of Thoracic Oncology
October 31, 2023
10.1016/j.jtho.2023.09.1210
Cited by 0

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
|Annals of Oncology|2020|443
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
|Annals of Oncology|2019|413
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|The Lancet Oncology|2020|413
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer
|Clinical Cancer Research|2020|381